<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01924065</url>
  </required_header>
  <id_info>
    <org_study_id>ozaydin291</org_study_id>
    <nct_id>NCT01924065</nct_id>
  </id_info>
  <brief_title>Risk of Stroke and Silent Cerebrovascular Thromboembolism After Cardioversion of Atrial Fibrillation</brief_title>
  <acronym>AFTER-CV</acronym>
  <official_title>Does Cardioversion of Atrial Fibrillation Increase the Risk of Stroke and Silent Cerebrovascular Thromboembolism? Comparison of the Two Cardioversion Methods</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suleyman Demirel University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suleyman Demirel University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with atrial fibrillation undergoing cardioversion will be randomized to undergo
      transesophageal echocardiography or they will receive warfarin for 3 weeks with an
      international normalized ratio (INR) value between 2.0-3.0. Those who do not want to use
      warfarin will be given an approved new oral anticoagulant agent istead of warfarin for 3
      weeks.

      If thrombus is detected in left atrium or in left atrial appendage, no cardioversion will be
      performed. Other patients in the both groups will undergo electrical cardioversion. After the
      procedures all the patients will be given oral anticoagulant for at least 4 Weeks. All
      patients will have neurological examination and diffusion magnetic resonance imaging (MRI) at
      baseline and at postprocedural 7th day. Clinical and subclinical cerebral thromboembolic
      events detected by diffusion MRI will be recorded. Any bleeding events will also be recorded.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ischemic stroke or silent cerebral thromboemboli</measure>
    <time_frame>1 week</time_frame>
    <description>clinical events or cerebral thromboemboli detected by diffusion magnetic resonance imaging</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Any clinical thromboembolic or hemorrhagic event or death</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">108</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Cardioversion</condition>
  <condition>Cerebrovascular Stroke</condition>
  <arm_group>
    <arm_group_label>Transesophageal Echocardiography group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm includes the patients with atrial fibrillation who undergo transesophageal echocardiography-guided cardioversion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral anticoagulant Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm includes the patients with atrial fibrillation who take warfarin or new oral anticoagulant agents three weeks before electrical cardioversion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cardioversion</intervention_name>
    <description>Electrical cardioversion</description>
    <arm_group_label>Transesophageal Echocardiography group</arm_group_label>
    <arm_group_label>Oral anticoagulant Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Anticoagulant</intervention_name>
    <description>warfarin, dabigatran etexilate, rivaroxaban, apixaban, edoxaban usage</description>
    <arm_group_label>Oral anticoagulant Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with the age of more than 18 years who are planned to undergo electrical or
             medical cardioversion

        Exclusion Criteria:

          -  Urgent cardioversion

          -  Patients who have implanted pace-makers or other metal devices

          -  Claustrophobia

          -  Hematological disorders disabling patients to receive anticoagulant agents

          -  Atrial fibrillation secondary to temporary causes.

          -  Serious rheumatic heart valve disease

          -  Hyperthyroidism

          -  History of malignancy

          -  Left atrium diameter &gt; 55 mm

          -  Ejection fraction &lt; 0.25
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mehmet Ozaydin, Professor,MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Suleyman Demirel University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Suleyman Demirel University</name>
      <address>
        <city>Isparta</city>
        <state>Mediterranean Region</state>
        <zip>32260</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 7, 2013</study_first_submitted>
  <study_first_submitted_qc>August 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2013</study_first_posted>
  <last_update_submitted>April 29, 2018</last_update_submitted>
  <last_update_submitted_qc>April 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Suleyman Demirel University</investigator_affiliation>
    <investigator_full_name>Mehmet Ozaydin, MD</investigator_full_name>
    <investigator_title>MD, Professor in Cardiology</investigator_title>
  </responsible_party>
  <keyword>Atrial fibrillation, conversion, stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

